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INTRODUCTION
Tetralogy of Fallot (TOF) is a most common cyanotic 
congenital heart disease characterized by ventricular 
septal defect (VSD), overriding of aorta, obstruction to 
right ventricular outflow tract and hypertrophy of right 
ventricle (1). Children with TOF are susceptible to serious 
neurological complications like cerebrovascular accidents 
(stroke) and brain abscess, which are mainly responsible 
for mortality and morbidity in these patients (1, 3). The 
incidence of cerebrovascular accidents and brain 
abscess in patients with TOF has been documented in 
Western literature as 8.6% and 13.7% respectively 2. 
Cerebrovascular accident is more common in children 
less than 2 years of age while brain abscess usually 
occur above 2 years of age. Brain abscess is a life 
threatening infection of brain parenchyma, but it is less 
common than cerebrovascular accidents because most 
patients of TOF are repaired at younger age (1). The 
extent of the neurological deficit depends largely upon 
the early detection of these complications. The early 
diagnosis of cerebrovascular accidents is important to 
prevent further recurrences (4), while the early detection 
of brain abscess is helpful for prompt management (5, 6). 
The advent of CT scan has resulted in fourfold decrease 
in mortality in these patients due to prompt identification 
and early intervention (7, 8). We observed that unlike 
developed countries, in developing countries like 
Pakistan children with TOF are more susceptible to 
adverse neurological complications especially the brain 
abscess due to delay in the surgical repair of TOF. 
To-date limited data is available regarding the frequency
of these complications in children with TOF. We 
speculated that by documenting the frequencies of 
these neurological complications, we can have high 
index of suspicion of these complications especially the 
brain abscess in patients of TOF. The early detection 
and prompt treatment of these patients will help in 
reducing the mortality and morbidity in them.
MATERIAL AND METHODS
It was a descriptive cross-sectional study done at the 
Pediatric Cardiology and Pediatric Neurology Depart-
ments of The Children’s Hospital and Institute of Child 
Health, Lahore from Dec 2009 to Nov 2010. Total 75 
unoperted echocardiographically proven cases of tetralogy
of fallot up to the age of 15 years presented with 
neurological manifestation were included in this study.
Patients are said to have neurological manifestation if 
they exhibit any one of the following i.e. persistent 
headache, unexplained recurrent vomiting, seizures, 
altered sensorium, hemeparesis, hemeplegia, aphasia,
cranial nerve involvement, nystagmus, ataxia, dysmetria 
or papilloedema on history and clinical examination. 
Patients presented with spell or operated for 
Blalock-Taussing shunt or primary repair were excluded 
from study. After taking informed consent by parents’ 
demographic data including age, gender and address 
were recorded on pre-designed Proforma. CT Brain with 
contrast was conducted in all these patients to look for 
cerebrovascular accident (hypodense non enhancing 
lesion) and brain abscess (hypodense ring enhancing 
focal lesion). The data was analyzed using SPSS v. 
12.0. A quantitative variable like age was presented by 
calculating mean and standard deviation. Qualitative 
variables like gender, cerebrovascular accident and 
brain abscess were presented by calculating frequencies 
and percentages.
RESULTS
Out of total 75 patients of Tetralogy of Fallot (TOF) 
presented with neurological manifestation 48 (64%) 
were having brain abscess, 24 (32%) were having 
cerebrovascular accident (CVA), 2 (2.6%) were having 
intracranial bleed and 1 (1.3%) was having 
meningoencephlitis (Table-1). Distribution of cases by 
age showed 14 cases (18.6%) were 0-2 years of ages 
of age, 7 cases (9.3%) were >2-5 years of age, 18 
cases (24%) were >5-10 years of age and 36 cases 
(48%) were >10-15 years of age with mean age of 
9.7±3 (Table–2). Disease breakdown of brain abscess 
according to age showed 3 cases (6.25%) were 0 – 2 
years of age, 4 cases (8.3%) were >2 – 5 years of age, 
11 cases (22.9%) were >5 – 10 years of age, and 30 
cases (62.5%) were >10 – 15 years of age with mean 
age of 10±3 years ( Table-2 ). Disease breakdown of 
cerebrovascular accident (CVA) according to age 
showed 13 cases (54%) were 0 – 2 years of age, 1 
cases (4.1%) were >2 – 5 years of age, 4 cases 
(16.6%) were >5 – 10 years of age, and 6 cases (25%) 
were >10 – 15 years of age with mean age of 4.7±3 
years ( Table-2 ). Distribution of cases by gender 
showed that 57 cases (76%) were male and 18 cases 
(24%) were female. Out of 48 cases of brain abscess 
38 (79.1%) were male and 10 (20.8%) were female. 
However among 24 cases of cerebrovascular accidents 
16 cases (66.6%) were male and 8 cases (33.3%) 
were female (Table-3).
DISCUSSION
Tetralogy of Fallot is a common cyanotic congenital 
heart disease, which occur in approximately 1 in 3600 
live birth and account for 3.5 % of infant born with 
congenital heart disease. It is diagnosed by 
echocardiography and characterized by ventricular 
septal defect (VSD), overriding of aorta, obstruction to 
right ventricular outflow tract and hypertrophy of right 
ventricle (9). The clinical presentation of tetralogy of 
fallot depends upon the severity of right ventricular 
outflow tract obstruction (RVOTO). When severe at 
birth, there is duct dependant pulmonary circulation 
and prostaglandin E is required to maintain duct 
patency. Moderate RVOTO give rise to a systolic murmur 
in an asymptomatic child. Cyanosis usually develops 
between 6-8 month as infundibular stenosis increases 
producing right to left shunt (9).
Children of tetralogy of fallot are susceptible to serious 
neurological manifestation like brain abscess (Figure-I) 
and cerebrovascular accidents (stroke) which contribute 
significantly to mortality and morbidity in them (10, 11). 
The main contributing factors for brain abscess in these 
childrens are chronic hypoxia leading to polycythemia, 
poor host immunity and bypass of lung phagocytes (12). 
However the risk factors for stroke include 
polycythemia, anemia, prolonged hypotension and 
dehydration (10, 13, 14). Children with tetralogy of fallot are 
susceptible to two types of strokes i.e. arterial and 
venous. Venous thrombosis is more common than 
arterial thrombosis. CT scan brain is the first line 
investigation to detect these neurological complications 
especially in emergency (15). In developed countries 
these neurological manifestations like brain abscess 
and stroke are very rare and their main focus has been 
shifted to neurological complications of cardiac surgery 
in the very young children as result of cardiopulmonary 
bypass and total hypothermic circulatory arrest. 
However in developing countries many of congenital 
heart diseases including tetralogy of fallot remain 
uncorrected and these neurological complications are 
frequently encountered (10). The main reason behind it is 
the delay in surgery resulting in chronic hypoxia leading 
to secondary polycythemia which is responsible for these 
neurological complications. More recently, the Toronto 
group encountered that optimal age for elective primary 
repair of tetralogy of fallot patients should be 3 to 11 
months (16). In one study by Hirsh et al it was reported 
that primary repair of tetralogy of fallot if done in 
neonatal age will lead to no neurological complications 
(17). Gender distribution observed in my study showed 
male predominance which was also demonstrated by 
Aebi et al (18) and Carpenter et al (19). In our study we 
collected 75 unoperated cases of tetralogy of fallot up 
to the age of 15 years presented with neurological 
manifestation in a period of 12 months. This is a large 
number of patients collected from single hospital 
because The Children’s Hospital and Institute of Child 
Health, Lahore is a tertiary care hospital with facilities of 
pediatric cardiology, pediatric neurology and pediatric 
neurosurgery and patients being referred from all over 
country. Another important reason for this large number 
of unoperated patients of tetralogy of fallot with 
neurological complications is that chronic hypoxia (due 
to delay in surgery) is main etiological factor behind 
these neurological complications. This fact was also 
supported by Mulder et al who suggested by earlier 
repair of these children we can reduce duration of 
hypoxia in them (20). In our study 48 out of 75 patients 
(64%) were found to have brain abscess and 24 out of 
75 patients (32%) were found to have cerebrovascular 
accident (stroke) (Table-1). This is contrary to Bernstein 
D who suggested that brain abscess is less common 
than cerebrovascular accidents in children with tetralogy 
of fallot and extremely rare today (1). However our 
findings are comparable with another study of 
unoperated cases of tetralogy of fallot where incidence 
of brain abscesses in more than cerebrovascular 
accident (2). In this study 14 cases out of 75 (18.6%) 
were >2 year, 7 cases out of 75 (9.3%) were between 
>2 to 5 years, 18 cases out of 75 (24%) were between 
>5year to 10 years and 36 cases out of 75 (48%) were 
> 10 year of age. So it showed that the risk of 
neurological complications increase with increasing age 
in unoperated case of TOF. In children > 2 year of age, 
3 out of 14 cases were found to have brain abscess 
and 13 cases were found to have cerebrovascular 
accident, showing CVA is more common than brain 
abscess in this age group. However in children >10 
year of age 30 cases out of 36 cases were found to 
have brain abscess and 6 cases were of 
cerebrovascular accident revealing brain abscess is 
more common in this age group. (Table-2) So, in our 
study brain abscess in more common in children above 
2 year of age and cerebrovascular accident more 
common in children less than 2 year of age. This age 
distribution was also observed by Bernstein D (1). In this 
study the frequency of brain abscess increases with 
increasing age (Table-2). However cerebrovascular 
accident is common in two age groups i.e. less than 2 
years (54%) and more than 10 year (25%). The reason 
for increased number of brain abscess than 
cerebrovascular accident in our study seems to be due 
to delay in their surgery in developing country like 
Pakistan, malnutrition leading to impaired host 
immunity, and very late presentation of unoperated 
tetralogy of fallot as most of cases are above 10 years 
of age. The early diagnosis of brain abscess is very 
important because prompt management can decrease 
mortality and morbidity in them (5, 6). It was reported that 
advent of CT scan brain resulted in fourfold decrease in 
mortality of patients of tetralogy of fallot with brain 
abscess (7, 8). In developing country like Pakistan where 
CT facility is not available everywhere it is judicial to 
start intravenous antibiotic for every patient of tetralogy 
of fallot presented with neurological manifestation until 
it is get ruled out by CT brain with contrast because 
prompt treatment of brain abscess  can reduce fatal 
outcomes and improve prognosis in these children.
CONCLUSION
Brain abscess and cerebrovascular accidents are common 
neurological complications in unoperated children of 
Tetralogy of Fallot which are responsible for mortality 
and morbidity in them. Frequency of brain abscess is 
found to be more than cerebrovascular accidents in 
these patients. So we should have a high index of 
suspicion of these neurological complications especially 
of brain abscess in every unoperated patient of Tetralogy 
of Fallot presented with neurological manifestation. 
Early detection of cerebrovascular accident prevents 
further such episodes, and prompt diagnosis and 
treatment of brain abscess lead to better outcome.
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As our patient had no previous history of MS, it was 
difficult to differentiate it from other varieties of 
malignant demyelinating diseases especially ADEM. 
However, historical data, CSF analysis and radiographic 
characteristics of lesions suggested fulminant MS 
(table 2) (20). Radiological images were almost diagnostic 
of tumefactive demyelinating process based on size 
(2cm or more), location (periventricular and juxtacortical) 
and nature of lesions (confluent areas, mixed T2 
weighted iso and hyperintensity of enhanced regions, 
absence of cortical involvement and absence of a mass 
effect) (14,15,21,22) The lesions can be multifocal (83%) 
(as in our case) or unifocal (17%)(13) CSF analysis in our 
patient revealed absence of pleocytosis with elevated 
protein and presence of oligoclonal bands which is 
present in 11% to 33% of tumefactive MS cases,(13) 
favouring our diagnosis of tumefactive MS over ADEM. (23) 
Biopsy of the lesions is not routinely recommended to 
make a histological diagnosis. Standard treatment 
approach for fulminant MS variants is similar to severe 
relapses of MS. However, due to the rarity and high 
mortality associated with Marburg variant of MS, only a 
limited number of case reports  have shown some 
promising results for Plasma exchange and Mitoxantrone 
as treatment for acute phase and prevention of further 
relapses (4,5,24) There is one published study of 
Fulminant MS from Pakistan also from our centre where 
patients were treated with IV immunoglobulins followed 
by Mitoxantrone, with good outcomes(22).
Fig 4.  Follow up of patient in neurology clinic 3 months 
later.
We used Plasma exchange (PLEX) in this patient due to 
financial constraints. Mitoxantrone is an immun- 
omodulatory agent used as a disease modifying drug 
(DMD) to improve neurological disability and delay 
progression in relapsing remitting MS and secondary 
progressive MS (21). Several randomized clinical trials 
used 12mg/m2 dose administered once every 3 
months (21). We have previously used mitoxantrone for 
management of relapsing remitting MS (23) and as a 
DMD for Fulminant MS.22 Though FMS is a disease of 
severe morbidity and high mortality but better outcome 
can be expected if treated promptly and aggressively 
with disease modifying therapies early in the course of 
the disease.
CONCLUSION
Due to limitation of resources in our country, PLEX 
followed by Mitoxantrone may be a valuable option for 
treatment of fulminant multiple sclerosis.
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came to be negative for malignancy. ANA was not done.
Patient showed gradual improvement in his clinical 
status and was discharged home 12 days later. He was 
given IV Mitoxantrone (12mg/m2), first dose given on 12 
day post admission and then once every 3 months. 
On discharge, EDSS improved from 9 to 5. He was 
followed in neurology clinic 3 months later with repeat 
MR imaging which showed interval regression in the size 
of previously noted lesions with no new activity (Fig.3). 
He showed remarkable clinical improvement, walking 
without support (EDSS 2) (Fig.4). He had no further 
relapse at 3 months.
DISCUSSION
Multiple sclerosis is the most common, idiopathic, 
inflammatory demyelinating disease of central nervous
system with a relapsing and remitting course (1)
Approximately 7% of patients may present with a 
fulminant disease (10). Tumefactive multiple sclerosis 
refers to large demyelinating lesions, typically 2 cm or 
larger in size, with surrounding mass effect, perilesional 
edema and open ring enhancement on gadolinium 
contrast (11,12,13). 
Figure 1. Axial diffusion weighted images(DWI) of Brain
(A) and (C) showing multiple nodular lesions of diffusion
restriction in bilateral parietal periventricular and 
subcortical regions, corresponding ADC images (B) 
and pons (D), largest one measuring 2.7×1.4 cm2.
They are iso-intense/hypointense on T1 (E) with subtle 
peripheral contrast enhancement (F) and correspondingly 
bright on FLAIR image with surrounding halo (G) and no 
significant mass effect.
First described nearly a century ago, Marburg variant of 
MS is a rare, acute, monophasic and highly aggressive 
form of MS, leading to severe morbidity or mortality 
within a few weeks to months.1 Due to its atypical 
clinical and radiographic features, it poses significant 
diagnostic dilemma (14). It presents with a polysymptomatic, 
monophasic illness (15) suggesting diffuse and extensive 
CNS involvement. 
Figure 2. Follow up MR images obtained 10 days later 
with new onset right hemiparesis and acute confusional 
state. DWI (A and C), ADC (B and D)and axial FLAIR 
images(E) showing development of new lesions and 
interval increase in size of previously observed multiple  
lesions which have become more confluent bilaterally.
Unlike classical MS, lesions occur simultaneously in all 
affected areas with large zones of confluent 
demyelination,(1,16) including cerebral hemisp- heres 
and brainstem (17) High mortality is associated with this 
variant especially with involvement of brainstem 
structures, (12,18,19) necessitating intensive care for 
aggressive management (15).First presentation of an 
acute, fulminant demyelinating event is the most 
common presentation in the course of tumefactive 
MS,13 hence early and prompt recognition of disease 
process and exclusion of infective, neoplastic, vasculitic and 
granulomatous disorder is of paramount importance.
Figure 3. Follow up MR images of same patient 
obtained at 3 months after resolution of acute neurological 
dysfunction. Axial T1 pre (A), post contrast (B) and FLAIR 
(C) images showing regression in size of previously noted 
lesions with no abnormal post contrast enhancement.
MARBURG VARIANT OF MULTIPLE SCLEROSIS; A DIAGNOSTIC
AND THERAPEUTIC CHALLENGE
ABSTRACT
Marburg variant of multiple sclerosis (MS) is a highly aggressive, fulminant demyelinating disease with very high morbidity 
and mortality. Early diagnosis and aggressive management is vital to limit severe disability and improve the outcome. 
We present a case of 35 years old male who presented with rapidly progressive demyelinating illness, leading to bed 
bound status over the course of a month. He was treated aggressively with intravenous (IV) steroids, plasma exchange 
(PLEX) and Mitoxantrone (MTX), leading to a remarkable recovery.
Key words: Multiple sclerosis, demyelinating, fulminant.
INTRODUCTION
Marburg variant of MS or Fulminant multiple sclerosis 
(FMS) is a rare but highly aggressive disease. It is 
characterized by rapidly progressive deterioration of 
neurological symptoms, sometimes, even weeks or 
months after the first attack (1). This results in progressive 
widespread white matter destruction in cerebral cortex 
but may even extend to involve vital brainstem structures 
(2,3). Management of FMS is very challenging as the 
outcome in many cases is either severe disability or 
death. Treatment options for FMS include high dose
corticosteroids, serial plasma exchange transfusions, 
immunoglobulins and disease modifying agents
(Mitoxantrone and Cyclophosphamide) (4,5,6,7,8,9). Patients 
also need intense involvement of various support 
services to help them during periods of disability. We 
present a case of acute FMS who showed relatively rapid 
and effective recovery when treated early and 
aggressively.
CASE REPORT
A 35 years, otherwise healthy gentleman was seen in our 
neurology clinic for sudden onset left hemiparesis, 
dysarthria, diplopia and blurring of vision lasting a few 
days followed by partial recovery. There was no history of 
fever or antecedent infection. He underwent cranial MR 
imaging which revealed multiple nodular lesions, 
isointense on T1 and hyperintense on FLAIR and T2 
weighted images suggesting a demyelinating disorder or 
metastatic disease (Fig.1). He was prescribed IV 
methylprednisolone 1gm once daily for 5 days. He did 
not start treatment immediately and took 2 doses only. 
10 days later, he presented to emergency department 
with new onset right hemiparesis, right UMN facial palsy, 
motor aphasia and acute confusional state. Repeat MR 
imaging showed interval increase in size of previously 
noted lesions plus new lesions suggestive of fulminant 
multiple sclerosis vs ADEM (Fig.2). He was severely 
disabled (EDSS 9) and was admitted to intensive care 
unit for aggressive therapy. CSF examination and Visual 
evoked potentials were also obtained (Table 1). He was 
given remaining 3 doses of IV methylprednisolone (1000 
mg) and was started on PLEX (250ml/kg divided over 7 
sessions; day 1,2,3,5,7,9,11). 
Aggressive speech therapy and physiotherapy were also
done. Metastatic workup was ordered with CT chest,
abdomen and pelvis as were other investigations that 
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Table 1. Pertinent Investigations
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Investigations Results 
ESR 1 mm/hour n=582
CBC TLC : 10,000/µl Hb : 16.70 g/dl Platelets :
   211,000/µl
CRP 4.66 mg/L
PSA 0.728 ng/mL
Creatinine 0.76 mg/dL
CSF analysis WBCs: <5 Protein: OG bands:
 cells/µL, 81.3mg/dL positive
ACE levels <5.0 U/L
LFTs T. Bilirubin: 0.7mg/dL,  ALT: 24, Alk.
 Phosphatase: 30U/L
Chem 7 (mEq/L) Sodium: 133,  Potassium: 3.9, Chloride: 99,
 Bicarbonate: 21
VEP (visual P100 values:
evoked  potentials) Right: 125.4 ms, Left: 130.8 ms
Vitreous examination No immune complexes seen in vitreous
CT chest, abdomen, Negative for malignancy /infection
and pelvis
INTRODUCTION
Tetralogy of Fallot (TOF) is a most common cyanotic 
congenital heart disease characterized by ventricular 
septal defect (VSD), overriding of aorta, obstruction to 
right ventricular outflow tract and hypertrophy of right 
ventricle (1). Children with TOF are susceptible to serious 
neurological complications like cerebrovascular accidents 
(stroke) and brain abscess, which are mainly responsible 
for mortality and morbidity in these patients (1, 3). The 
incidence of cerebrovascular accidents and brain 
abscess in patients with TOF has been documented in 
Western literature as 8.6% and 13.7% respectively 2. 
Cerebrovascular accident is more common in children 
less than 2 years of age while brain abscess usually 
occur above 2 years of age. Brain abscess is a life 
threatening infection of brain parenchyma, but it is less 
common than cerebrovascular accidents because most 
patients of TOF are repaired at younger age (1). The 
extent of the neurological deficit depends largely upon 
the early detection of these complications. The early 
diagnosis of cerebrovascular accidents is important to 
prevent further recurrences (4), while the early detection 
of brain abscess is helpful for prompt management (5, 6). 
The advent of CT scan has resulted in fourfold decrease 
in mortality in these patients due to prompt identification 
and early intervention (7, 8). We observed that unlike 
developed countries, in developing countries like 
Pakistan children with TOF are more susceptible to 
adverse neurological complications especially the brain 
abscess due to delay in the surgical repair of TOF. 
To-date limited data is available regarding the frequency
of these complications in children with TOF. We 
speculated that by documenting the frequencies of 
these neurological complications, we can have high 
index of suspicion of these complications especially the 
brain abscess in patients of TOF. The early detection 
and prompt treatment of these patients will help in 
reducing the mortality and morbidity in them.
MATERIAL AND METHODS
It was a descriptive cross-sectional study done at the 
Pediatric Cardiology and Pediatric Neurology Depart-
ments of The Children’s Hospital and Institute of Child 
Health, Lahore from Dec 2009 to Nov 2010. Total 75 
unoperted echocardiographically proven cases of tetralogy
of fallot up to the age of 15 years presented with 
neurological manifestation were included in this study.
Patients are said to have neurological manifestation if 
they exhibit any one of the following i.e. persistent 
headache, unexplained recurrent vomiting, seizures, 
altered sensorium, hemeparesis, hemeplegia, aphasia,
cranial nerve involvement, nystagmus, ataxia, dysmetria 
or papilloedema on history and clinical examination. 
Patients presented with spell or operated for 
Blalock-Taussing shunt or primary repair were excluded 
from study. After taking informed consent by parents’ 
demographic data including age, gender and address 
were recorded on pre-designed Proforma. CT Brain with 
contrast was conducted in all these patients to look for 
cerebrovascular accident (hypodense non enhancing 
lesion) and brain abscess (hypodense ring enhancing 
focal lesion). The data was analyzed using SPSS v. 
12.0. A quantitative variable like age was presented by 
calculating mean and standard deviation. Qualitative 
variables like gender, cerebrovascular accident and 
brain abscess were presented by calculating frequencies 
and percentages.
RESULTS
Out of total 75 patients of Tetralogy of Fallot (TOF) 
presented with neurological manifestation 48 (64%) 
were having brain abscess, 24 (32%) were having 
cerebrovascular accident (CVA), 2 (2.6%) were having 
intracranial bleed and 1 (1.3%) was having 
meningoencephlitis (Table-1). Distribution of cases by 
age showed 14 cases (18.6%) were 0-2 years of ages 
of age, 7 cases (9.3%) were >2-5 years of age, 18 
cases (24%) were >5-10 years of age and 36 cases 
(48%) were >10-15 years of age with mean age of 
9.7±3 (Table–2). Disease breakdown of brain abscess 
according to age showed 3 cases (6.25%) were 0 – 2 
years of age, 4 cases (8.3%) were >2 – 5 years of age, 
11 cases (22.9%) were >5 – 10 years of age, and 30 
cases (62.5%) were >10 – 15 years of age with mean 
age of 10±3 years ( Table-2 ). Disease breakdown of 
cerebrovascular accident (CVA) according to age 
showed 13 cases (54%) were 0 – 2 years of age, 1 
cases (4.1%) were >2 – 5 years of age, 4 cases 
(16.6%) were >5 – 10 years of age, and 6 cases (25%) 
were >10 – 15 years of age with mean age of 4.7±3 
years ( Table-2 ). Distribution of cases by gender 
showed that 57 cases (76%) were male and 18 cases 
(24%) were female. Out of 48 cases of brain abscess 
38 (79.1%) were male and 10 (20.8%) were female. 
However among 24 cases of cerebrovascular accidents 
16 cases (66.6%) were male and 8 cases (33.3%) 
were female (Table-3).
DISCUSSION
Tetralogy of Fallot is a common cyanotic congenital 
heart disease, which occur in approximately 1 in 3600 
live birth and account for 3.5 % of infant born with 
congenital heart disease. It is diagnosed by 
echocardiography and characterized by ventricular 
septal defect (VSD), overriding of aorta, obstruction to 
right ventricular outflow tract and hypertrophy of right 
ventricle (9). The clinical presentation of tetralogy of 
fallot depends upon the severity of right ventricular 
outflow tract obstruction (RVOTO). When severe at 
birth, there is duct dependant pulmonary circulation 
and prostaglandin E is required to maintain duct 
patency. Moderate RVOTO give rise to a systolic murmur 
in an asymptomatic child. Cyanosis usually develops 
between 6-8 month as infundibular stenosis increases 
producing right to left shunt (9).
Children of tetralogy of fallot are susceptible to serious 
neurological manifestation like brain abscess (Figure-I) 
and cerebrovascular accidents (stroke) which contribute 
significantly to mortality and morbidity in them (10, 11). 
The main contributing factors for brain abscess in these 
childrens are chronic hypoxia leading to polycythemia, 
poor host immunity and bypass of lung phagocytes (12). 
However the risk factors for stroke include 
polycythemia, anemia, prolonged hypotension and 
dehydration (10, 13, 14). Children with tetralogy of fallot are 
susceptible to two types of strokes i.e. arterial and 
venous. Venous thrombosis is more common than 
arterial thrombosis. CT scan brain is the first line 
investigation to detect these neurological complications 
especially in emergency (15). In developed countries 
these neurological manifestations like brain abscess 
and stroke are very rare and their main focus has been 
shifted to neurological complications of cardiac surgery 
in the very young children as result of cardiopulmonary 
bypass and total hypothermic circulatory arrest. 
However in developing countries many of congenital 
heart diseases including tetralogy of fallot remain 
uncorrected and these neurological complications are 
frequently encountered (10). The main reason behind it is 
the delay in surgery resulting in chronic hypoxia leading 
to secondary polycythemia which is responsible for these 
neurological complications. More recently, the Toronto 
group encountered that optimal age for elective primary 
repair of tetralogy of fallot patients should be 3 to 11 
months (16). In one study by Hirsh et al it was reported 
that primary repair of tetralogy of fallot if done in 
neonatal age will lead to no neurological complications 
(17). Gender distribution observed in my study showed 
male predominance which was also demonstrated by 
Aebi et al (18) and Carpenter et al (19). In our study we 
collected 75 unoperated cases of tetralogy of fallot up 
to the age of 15 years presented with neurological 
manifestation in a period of 12 months. This is a large 
number of patients collected from single hospital 
because The Children’s Hospital and Institute of Child 
Health, Lahore is a tertiary care hospital with facilities of 
pediatric cardiology, pediatric neurology and pediatric 
neurosurgery and patients being referred from all over 
country. Another important reason for this large number 
of unoperated patients of tetralogy of fallot with 
neurological complications is that chronic hypoxia (due 
to delay in surgery) is main etiological factor behind 
these neurological complications. This fact was also 
supported by Mulder et al who suggested by earlier 
repair of these children we can reduce duration of 
hypoxia in them (20). In our study 48 out of 75 patients 
(64%) were found to have brain abscess and 24 out of 
75 patients (32%) were found to have cerebrovascular 
accident (stroke) (Table-1). This is contrary to Bernstein 
D who suggested that brain abscess is less common 
than cerebrovascular accidents in children with tetralogy 
of fallot and extremely rare today (1). However our 
findings are comparable with another study of 
unoperated cases of tetralogy of fallot where incidence 
of brain abscesses in more than cerebrovascular 
accident (2). In this study 14 cases out of 75 (18.6%) 
were >2 year, 7 cases out of 75 (9.3%) were between 
>2 to 5 years, 18 cases out of 75 (24%) were between 
>5year to 10 years and 36 cases out of 75 (48%) were 
> 10 year of age. So it showed that the risk of 
neurological complications increase with increasing age 
in unoperated case of TOF. In children > 2 year of age, 
3 out of 14 cases were found to have brain abscess 
and 13 cases were found to have cerebrovascular 
accident, showing CVA is more common than brain 
abscess in this age group. However in children >10 
year of age 30 cases out of 36 cases were found to 
have brain abscess and 6 cases were of 
cerebrovascular accident revealing brain abscess is 
more common in this age group. (Table-2) So, in our 
study brain abscess in more common in children above 
2 year of age and cerebrovascular accident more 
common in children less than 2 year of age. This age 
distribution was also observed by Bernstein D (1). In this 
study the frequency of brain abscess increases with 
increasing age (Table-2). However cerebrovascular 
accident is common in two age groups i.e. less than 2 
years (54%) and more than 10 year (25%). The reason 
for increased number of brain abscess than 
cerebrovascular accident in our study seems to be due 
to delay in their surgery in developing country like 
Pakistan, malnutrition leading to impaired host 
immunity, and very late presentation of unoperated 
tetralogy of fallot as most of cases are above 10 years 
of age. The early diagnosis of brain abscess is very 
important because prompt management can decrease 
mortality and morbidity in them (5, 6). It was reported that 
advent of CT scan brain resulted in fourfold decrease in 
mortality of patients of tetralogy of fallot with brain 
abscess (7, 8). In developing country like Pakistan where 
CT facility is not available everywhere it is judicial to 
start intravenous antibiotic for every patient of tetralogy 
of fallot presented with neurological manifestation until 
it is get ruled out by CT brain with contrast because 
prompt treatment of brain abscess  can reduce fatal 
outcomes and improve prognosis in these children.
CONCLUSION
Brain abscess and cerebrovascular accidents are common 
neurological complications in unoperated children of 
Tetralogy of Fallot which are responsible for mortality 
and morbidity in them. Frequency of brain abscess is 
found to be more than cerebrovascular accidents in 
these patients. So we should have a high index of 
suspicion of these neurological complications especially 
of brain abscess in every unoperated patient of Tetralogy 
of Fallot presented with neurological manifestation. 
Early detection of cerebrovascular accident prevents 
further such episodes, and prompt diagnosis and 
treatment of brain abscess lead to better outcome.
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As our patient had no previous history of MS, it was 
difficult to differentiate it from other varieties of 
malignant demyelinating diseases especially ADEM. 
However, historical data, CSF analysis and radiographic 
characteristics of lesions suggested fulminant MS 
(table 2) (20). Radiological images were almost diagnostic 
of tumefactive demyelinating process based on size 
(2cm or more), location (periventricular and juxtacortical) 
and nature of lesions (confluent areas, mixed T2 
weighted iso and hyperintensity of enhanced regions, 
absence of cortical involvement and absence of a mass 
effect) (14,15,21,22) The lesions can be multifocal (83%) 
(as in our case) or unifocal (17%)(13) CSF analysis in our 
patient revealed absence of pleocytosis with elevated 
protein and presence of oligoclonal bands which is 
present in 11% to 33% of tumefactive MS cases,(13) 
favouring our diagnosis of tumefactive MS over ADEM. (23) 
Biopsy of the lesions is not routinely recommended to 
make a histological diagnosis. Standard treatment 
approach for fulminant MS variants is similar to severe 
relapses of MS. However, due to the rarity and high 
mortality associated with Marburg variant of MS, only a 
limited number of case reports  have shown some 
promising results for Plasma exchange and Mitoxantrone 
as treatment for acute phase and prevention of further 
relapses (4,5,24) There is one published study of 
Fulminant MS from Pakistan also from our centre where 
patients were treated with IV immunoglobulins followed 
by Mitoxantrone, with good outcomes(22).
Fig 4.  Follow up of patient in neurology clinic 3 months 
later.
We used Plasma exchange (PLEX) in this patient due to 
financial constraints. Mitoxantrone is an immun- 
omodulatory agent used as a disease modifying drug 
(DMD) to improve neurological disability and delay 
progression in relapsing remitting MS and secondary 
progressive MS (21). Several randomized clinical trials 
used 12mg/m2 dose administered once every 3 
months (21). We have previously used mitoxantrone for 
management of relapsing remitting MS (23) and as a 
DMD for Fulminant MS.22 Though FMS is a disease of 
severe morbidity and high mortality but better outcome 
can be expected if treated promptly and aggressively 
with disease modifying therapies early in the course of 
the disease.
CONCLUSION
Due to limitation of resources in our country, PLEX 
followed by Mitoxantrone may be a valuable option for 
treatment of fulminant multiple sclerosis.
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came to be negative for malignancy. ANA was not done.
Patient showed gradual improvement in his clinical 
status and was discharged home 12 days later. He was 
given IV Mitoxantrone (12mg/m2), first dose given on 12 
day post admission and then once every 3 months. 
On discharge, EDSS improved from 9 to 5. He was 
followed in neurology clinic 3 months later with repeat 
MR imaging which showed interval regression in the size 
of previously noted lesions with no new activity (Fig.3). 
He showed remarkable clinical improvement, walking 
without support (EDSS 2) (Fig.4). He had no further 
relapse at 3 months.
DISCUSSION
Multiple sclerosis is the most common, idiopathic, 
inflammatory demyelinating disease of central nervous
system with a relapsing and remitting course (1)
Approximately 7% of patients may present with a 
fulminant disease (10). Tumefactive multiple sclerosis 
refers to large demyelinating lesions, typically 2 cm or 
larger in size, with surrounding mass effect, perilesional 
edema and open ring enhancement on gadolinium 
contrast (11,12,13). 
Figure 1. Axial diffusion weighted images(DWI) of Brain
(A) and (C) showing multiple nodular lesions of diffusion
restriction in bilateral parietal periventricular and 
subcortical regions, corresponding ADC images (B) 
and pons (D), largest one measuring 2.7×1.4 cm2.
They are iso-intense/hypointense on T1 (E) with subtle 
peripheral contrast enhancement (F) and correspondingly 
bright on FLAIR image with surrounding halo (G) and no 
significant mass effect.
First described nearly a century ago, Marburg variant of 
MS is a rare, acute, monophasic and highly aggressive 
form of MS, leading to severe morbidity or mortality 
within a few weeks to months.1 Due to its atypical 
clinical and radiographic features, it poses significant 
diagnostic dilemma (14). It presents with a polysymptomatic, 
monophasic illness (15) suggesting diffuse and extensive 
CNS involvement. 
Figure 2. Follow up MR images obtained 10 days later 
with new onset right hemiparesis and acute confusional 
state. DWI (A and C), ADC (B and D)and axial FLAIR 
images(E) showing development of new lesions and 
interval increase in size of previously observed multiple  
lesions which have become more confluent bilaterally.
Unlike classical MS, lesions occur simultaneously in all 
affected areas with large zones of confluent 
demyelination,(1,16) including cerebral hemisp- heres 
and brainstem (17) High mortality is associated with this 
variant especially with involvement of brainstem 
structures, (12,18,19) necessitating intensive care for 
aggressive management (15).First presentation of an 
acute, fulminant demyelinating event is the most 
common presentation in the course of tumefactive 
MS,13 hence early and prompt recognition of disease 
process and exclusion of infective, neoplastic, vasculitic and 
granulomatous disorder is of paramount importance.
Figure 3. Follow up MR images of same patient 
obtained at 3 months after resolution of acute neurological 
dysfunction. Axial T1 pre (A), post contrast (B) and FLAIR 
(C) images showing regression in size of previously noted 
lesions with no abnormal post contrast enhancement.
Table 2. Differences between MS and ADEM
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Characteristics ADEM MS
Age <8 years ≥8-10 years
Antecedent infection usual unusual
Encephalopathy Common  Uncommon 
CSF pleocytosis Prominent  Uncommon 
Oligoclonal bands Absent Present
MR imaging  Common Uncommon
(gray matter involvement             
Course Monophasic, Multiphasic, progressive,
 Non-progressive Relapsing & remitting
Disease modifying Not required Required to prevent 
therapy  relapses
As our patient had no previous history of MS, it was 
difficult to differentiate it from other varieties of 
malignant demyelinating diseases especially ADEM. 
However, historical data, CSF analysis and radiographic 
characteristics of lesions suggested fulminant MS 
(table 2) (20). Radiological images were almost diagnostic 
of tumefactive demyelinating process based on size 
(2cm or more), location (periventricular and juxtacortical) 
and nature of lesions (confluent areas, mixed T2 
weighted iso and hyperintensity of enhanced regions, 
absence of cortical involvement and absence of a mass 
effect) (14,15,21,22) The lesions can be multifocal (83%) 
(as in our case) or unifocal (17%)(13) CSF analysis in our 
patient revealed absence of pleocytosis with elevated 
protein and presence of oligoclonal bands which is 
present in 11% to 33% of tumefactive MS cases,(13) 
favouring our diagnosis of tumefactive MS over ADEM. (23) 
Biopsy of the lesions is not routinely recommended to 
make a histological diagnosis. Standard treatment 
approach for fulminant MS variants is similar to severe 
relapses of MS. However, due to the rarity and high 
mortality associated with Marburg variant of MS, only a 
limited number of case reports  have shown some 
promising results for Plasma exchange and Mitoxantrone 
as treatment for acute phase and prevention of further 
relapses (4,5,24) There is one published study of 
Fulminant MS from Pakistan also from our centre where 
patients were treated with IV immunoglobulins followed 
by Mitoxantrone, with good outcomes(22).
Fig 4.  Follow up of patient in neurology clinic 3 months 
later.
We used Plasma exchange (PLEX) in this patient due to 
financial constraints. Mitoxantrone is an immun- 
omodulatory agent used as a disease modifying drug 
(DMD) to improve neurological disability and delay 
progression in relapsing remitting MS and secondary 
progressive MS (21). Several randomized clinical trials 
used 12mg/m2 dose administered once every 3 
months (21). We have previously used mitoxantrone for 
management of relapsing remitting MS (23) and as a 
DMD for Fulminant MS.22 Though FMS is a disease of 
severe morbidity and high mortality but better outcome 
can be expected if treated promptly and aggressively 
with disease modifying therapies early in the course of 
the disease.
CONCLUSION
Due to limitation of resources in our country, PLEX 
followed by Mitoxantrone may be a valuable option for 
treatment of fulminant multiple sclerosis.
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came to be negative for malignancy. ANA was not done.
Patient showed gradual improvement in his clinical 
status and was discharged home 12 days later. He was 
given IV Mitoxantrone (12mg/m2), first dose given on 12 
day post admission and then once every 3 months. 
On discharge, EDSS improved from 9 to 5. He was 
followed in neurology clinic 3 months later with repeat 
MR imaging which showed interval regression in the size 
of previously noted lesions with no new activity (Fig.3). 
He showed remarkable clinical improvement, walking 
without support (EDSS 2) (Fig.4). He had no further 
relapse at 3 months.
DISCUSSION
Multiple sclerosis is the most common, idiopathic, 
inflammatory demyelinating disease of central nervous
system with a relapsing and remitting course (1)
Approximately 7% of patients may present with a 
fulminant disease (10). Tumefactive multiple sclerosis 
refers to large demyelinating lesions, typically 2 cm or 
larger in size, with surrounding mass effect, perilesional 
edema and open ring enhancement on gadolinium 
contrast (11,12,13). 
Figure 1. Axial diffusion weighted images(DWI) of Brain
(A) and (C) showing multiple nodular lesions of diffusion
restriction in bilateral parietal periventricular and 
subcortical regions, corresponding ADC images (B) 
and pons (D), largest one measuring 2.7×1.4 cm2.
They are iso-intense/hypointense on T1 (E) with subtle 
peripheral contrast enhancement (F) and correspondingly 
bright on FLAIR image with surrounding halo (G) and no 
significant mass effect.
First described nearly a century ago, Marburg variant of 
MS is a rare, acute, monophasic and highly aggressive 
form of MS, leading to severe morbidity or mortality 
within a few weeks to months.1 Due to its atypical 
clinical and radiographic features, it poses significant 
diagnostic dilemma (14). It presents with a polysymptomatic, 
monophasic illness (15) suggesting diffuse and extensive 
CNS involvement. 
Figure 2. Follow up MR images obtained 10 days later 
with new onset right hemiparesis and acute confusional 
state. DWI (A and C), ADC (B and D)and axial FLAIR 
images(E) showing development of new lesions and 
interval increase in size of previously observed multiple  
lesions which have become more confluent bilaterally.
Unlike classical MS, lesions occur simultaneously in all 
affected areas with large zones of confluent 
demyelination,(1,16) including cerebral hemisp- heres 
and brainstem (17) High mortality is associated with this 
variant especially with involvement of brainstem 
structures, (12,18,19) necessitating intensive care for 
aggressive management (15).First presentation of an 
acute, fulminant demyelinating event is the most 
common presentation in the course of tumefactive 
MS,13 hence early and prompt recognition of disease 
process and exclusion of infective, neoplastic, vasculitic and 
granulomatous disorder is of paramount importance.
Figure 3. Follow up MR images of same patient 
obtained at 3 months after resolution of acute neurological 
dysfunction. Axial T1 pre (A), post contrast (B) and FLAIR 
(C) images showing regression in size of previously noted 
lesions with no abnormal post contrast enhancement.
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(as in our case) or unifocal (17%)(13) CSF analysis in our 
patient revealed absence of pleocytosis with elevated 
protein and presence of oligoclonal bands which is 
present in 11% to 33% of tumefactive MS cases,(13) 
favouring our diagnosis of tumefactive MS over ADEM. (23) 
Biopsy of the lesions is not routinely recommended to 
make a histological diagnosis. Standard treatment 
approach for fulminant MS variants is similar to severe 
relapses of MS. However, due to the rarity and high 
mortality associated with Marburg variant of MS, only a 
limited number of case reports  have shown some 
promising results for Plasma exchange and Mitoxantrone 
as treatment for acute phase and prevention of further 
relapses (4,5,24) There is one published study of 
Fulminant MS from Pakistan also from our centre where 
patients were treated with IV immunoglobulins followed 
by Mitoxantrone, with good outcomes(22).
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We used Plasma exchange (PLEX) in this patient due to 
financial constraints. Mitoxantrone is an immun- 
omodulatory agent used as a disease modifying drug 
(DMD) to improve neurological disability and delay 
progression in relapsing remitting MS and secondary 
progressive MS (21). Several randomized clinical trials 
used 12mg/m2 dose administered once every 3 
months (21). We have previously used mitoxantrone for 
management of relapsing remitting MS (23) and as a 
DMD for Fulminant MS.22 Though FMS is a disease of 
severe morbidity and high mortality but better outcome 
can be expected if treated promptly and aggressively 
with disease modifying therapies early in the course of 
the disease.
CONCLUSION
Due to limitation of resources in our country, PLEX 
followed by Mitoxantrone may be a valuable option for 
treatment of fulminant multiple sclerosis.
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came to be negative for malignancy. ANA was not done.
Patient showed gradual improvement in his clinical 
status and was discharged home 12 days later. He was 
given IV Mitoxantrone (12mg/m2), first dose given on 12 
day post admission and then once every 3 months. 
On discharge, EDSS improved from 9 to 5. He was 
followed in neurology clinic 3 months later with repeat 
MR imaging which showed interval regression in the size 
of previously noted lesions with no new activity (Fig.3). 
He showed remarkable clinical improvement, walking 
without support (EDSS 2) (Fig.4). He had no further 
relapse at 3 months.
DISCUSSION
Multiple sclerosis is the most common, idiopathic, 
inflammatory demyelinating disease of central nervous
system with a relapsing and remitting course (1)
Approximately 7% of patients may present with a 
fulminant disease (10). Tumefactive multiple sclerosis 
refers to large demyelinating lesions, typically 2 cm or 
larger in size, with surrounding mass effect, perilesional 
edema and open ring enhancement on gadolinium 
contrast (11,12,13). 
Figure 1. Axial diffusion weighted images(DWI) of Brain
(A) and (C) showing multiple nodular lesions of diffusion
restriction in bilateral parietal periventricular and 
subcortical regions, corresponding ADC images (B) 
and pons (D), largest one measuring 2.7×1.4 cm2.
They are iso-intense/hypointense on T1 (E) with subtle 
peripheral contrast enhancement (F) and correspondingly 
bright on FLAIR image with surrounding halo (G) and no 
significant mass effect.
First described nearly a century ago, Marburg variant of 
MS is a rare, acute, monophasic and highly aggressive 
form of MS, leading to severe morbidity or mortality 
within a few weeks to months.1 Due to its atypical 
clinical and radiographic features, it poses significant 
diagnostic dilemma (14). It presents with a polysymptomatic, 
monophasic illness (15) suggesting diffuse and extensive 
CNS involvement. 
Figure 2. Follow up MR images obtained 10 days later 
with new onset right hemiparesis and acute confusional 
state. DWI (A and C), ADC (B and D)and axial FLAIR 
images(E) showing development of new lesions and 
interval increase in size of previously observed multiple  
lesions which have become more confluent bilaterally.
Unlike classical MS, lesions occur simultaneously in all 
affected areas with large zones of confluent 
demyelination,(1,16) including cerebral hemisp- heres 
and brainstem (17) High mortality is associated with this 
variant especially with involvement of brainstem 
structures, (12,18,19) necessitating intensive care for 
aggressive management (15).First presentation of an 
acute, fulminant demyelinating event is the most 
common presentation in the course of tumefactive 
MS,13 hence early and prompt recognition of disease 
process and exclusion of infective, neoplastic, vasculitic and 
granulomatous disorder is of paramount importance.
Figure 3. Follow up MR images of same patient 
obtained at 3 months after resolution of acute neurological 
dysfunction. Axial T1 pre (A), post contrast (B) and FLAIR 
(C) images showing regression in size of previously noted 
lesions with no abnormal post contrast enhancement.
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